Business
Result of General Meeting and Total Voting Rights
Result of General Meeting and Total Voting Rights.
About this update from Fusion Antibodies Plc
[{"type":"text","content":"\n\n\n\n \nFusion Antibodies plc\n(\"Fusion\" or the \"Company\")\n \nResult of General Meeting\nand\nTotal Voting Rights\n \nFusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that at the general meeting of the Company, held earlier today, all resolutions were duly passed.\n \nFollowing the passing of the resolutions, the Company has raised a total of £1,375,000 pursuant to the Placing, details of which were announced by the Company on 14 February 2024.\n \nApplication has been made for admission of the 34,375,000 Placing Shares to trading on AIM (\"Admission\"). It is currently anticipated that Admission will become effective and that dealings in the Placing Shares will commence on AIM at 8.00 a.m. on 7 March 2024.\n \nTotal voting rights\n \nFollowing Admission, the number of ordinary shares of 4p each in the capital of the Company (the \"Ordinary Shares\") in issue and number of voting rights will be 95,365,564. The above figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.\n \nTerms used but not defined in this announcement have the same meaning as set out in the Company's announcement released at 07:00 on 14 February 2024.\n \nEnquiries: \n \n\n\n\n\nFusion Antibodies plc\n\n\nwww.fusionantibodies.com\n\n\n\n\nAdrian Kinkaid, Chief Executive Officer\nStephen Smyth, Chief Financial Officer\n\n\nVia Walbrook PR\n\n\n\n\n \n\n\n\n\n\n\n\nAllenby Capital Limited\n\n\nTel: +44 (0)20 3328 5656 \n\n\n\n\nJames Reeve/Vivek Bhardwaj (Corporate Finance)\nTony Quirke/Joscelin Pinnington (Sales and Corporate Broking)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n\nShard Capital Partners LLP\n\n\n\n\n\n\n\nDamon Heath (Joint Broker)\n\n\nTel: +44 (0)207 186 9952\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n\nWalbrook PR\n\n\nTel: +44 (0)20 7933 8780 or [email protected]\n\n\n\n\nAnna Dunphy\n\n\nMob: +44 (0)7876 741 001\n\n\n\n\n\n\n\n\n\n \n \nAbout Fusion Antibodies plc\n \nFusion is a Be...